Structure Therapeutics GPCR
$16.13 −$0.99 (-5.78%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $16.69 +3.47%
Open$16.73
Prev close$17.12
Day range$16.06 – $17.08
Volume786.2K
Market cap$1.15B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$156.33M-111.9% YoY
Net profit-$144.76M-120.3% YoY
Diluted EPS-$1.98-78.4% YoY
Free cash flow-$105.35M-100.4% YoY
Operating cash flow-$101.70M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-29.5%
Return on assets-27.1%
Return on invested capital-29.3%
Current ratio11.91
Liabilities / assets8.4%
Cash & investments$1.24B
Total debt$4.07M
Net cash (debt)$1.24B
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $156.33M | $118.63M | $89.38M | $186.81M | -$13.74M |
| Selling and Admin Expenses | $21.78M | $18.57M | $22.87M | $61.55M | $17.57M |
| -General & Admin Expense | $21.78M | $18.57M | $22.87M | $61.55M | $17.57M |
| Research & Development | $134.55M | $100.06M | $66.51M | $225.26M | $68.69M |
| Operating Profit | -$156.33M | -$118.63M | -$89.38M | -$186.81M | $13.74M |
| Net Non-Operating Interest Income (Expense) | $11.75M | $12.71M | $13.60M | $35.87M | $9.19M |
| Total Other Finance Costs | -$11.75M | -$12.71M | -$13.60M | -$35.87M | -$9.19M |
| Pretax Profit | -$144.59M | -$105.93M | -$75.78M | -$140.69M | $33.17M |
| Tax | $171,000.00 | $234,000.00 | $190,000.00 | $515,000.00 | $170,000.00 |
| Net Profit | -$144.76M | -$106.16M | -$75.97M | -$141.20M | $33.00M |
| Profit from Continuing Operations | -$144.76M | -$106.16M | -$75.97M | -$141.20M | $33.00M |
| Net Income to Parent Company | -$144.76M | -$106.16M | -$75.97M | -$141.20M | $33.00M |
| Net Income to Common Stockholders | -$144.76M | -$106.16M | -$75.97M | -$141.20M | $33.00M |
| Basic EPS | -$1.98 | -$1.47 | -$1.05 | -$2.40 | $0.47 |
| Diluted EPS | -$1.98 | -$1.47 | -$1.05 | -$2.40 | $0.47 |
| Other Operating Expenses | – | – | – | -$100.00M | – |
| Other Income (Expense) | – | – | – | $10.25M | – |
| Special Income (Charges) | – | – | – | $10.25M | – |
| -Gain on Sale of Property/Plant/Equipment | – | – | – | $10.25M | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.33B | $1.43B | $1.51B | $1.58B | $1.58B |
| Total Current Assets | $1.28B | $1.37B | $1.49B | $1.57B | $1.57B |
| Cash and Cash Equivalents & Short-Term Investments | $1.24B | $1.34B | $1.46B | $1.45B | $1.45B |
| -Cash and Cash Equivalents | $222.03M | $272.64M | $316.17M | $799.62M | $799.62M |
| -Short Term Investments | $1.02B | $1.07B | $1.14B | $646.57M | $646.57M |
| Receivables | $0.00 | $0.00 | $0.00 | $100.00M | $100.00M |
| Other Current Assets | $35.15M | $29.37M | $32.09M | $24.11M | $24.11M |
| Total Non-Current Assets | $59.29M | $53.39M | $17.53M | $13.62M | $13.62M |
| Net PPE | $16.84M | $12.39M | $11.97M | $12.90M | $12.90M |
| -Gross PPE | $16.84M | $12.39M | $11.97M | $15.87M | $15.87M |
| Other Non-Current Assets | $42.46M | $41.00M | $5.56M | $717,000.00 | $717,000.00 |
| Total Liabilities | $112.55M | $71.01M | $61.03M | $67.54M | $67.54M |
| Total Current Liabilities | $107.10M | $66.11M | $56.98M | $63.29M | $63.29M |
| Payables | $33.88M | $11.13M | $7.82M | $13.86M | $13.86M |
| -Accounts Payable | $33.88M | $11.13M | $7.82M | $13.86M | $13.86M |
| Current Accrued Expenses | $58.33M | $44.37M | $40.19M | $34.11M | $34.11M |
| Short-Term Debt and Capital Lease Obligation | $2.76M | $2.60M | $2.61M | $2.88M | $2.88M |
| -Current Capital Lease Obligation | $2.76M | $2.60M | $2.61M | $2.88M | $2.88M |
| Total Non-Current Liabilities | $5.45M | $4.90M | $4.05M | $4.26M | $4.26M |
| Long Term Debt and Capital Lease Obligation | $4.07M | $3.63M | $3.18M | $3.61M | $3.61M |
| -Long Term Capital Lease Obligation | $4.07M | $3.63M | $3.18M | $3.61M | $3.61M |
| Other Non-Current Liabilities | $1.38M | $1.27M | $863,000.00 | $647,000.00 | $647,000.00 |
| Total Equity | $1.22B | $1.35B | $1.45B | $1.52B | $1.52B |
| Stockholders' Equity | $1.22B | $1.35B | $1.45B | $1.52B | $1.52B |
| Capital Stock | $21,000.00 | $21,000.00 | $21,000.00 | $21,000.00 | $21,000.00 |
| -Common Stock | $21,000.00 | $21,000.00 | $21,000.00 | $21,000.00 | $21,000.00 |
| Additional Paid-In Capital | $2.02B | $2.01B | $2.00B | $1.99B | $1.99B |
| Retained Earnings | -$797.18M | -$652.43M | -$546.27M | -$470.30M | -$470.30M |
| Gains/Losses Not Affecting Retained Earnings | -$4.69M | -$3.45M | -$2.20M | $1.05M | $1.05M |
| -Other Receivables | – | – | – | $100.00M | $100.00M |
| -Accumulated Depreciation | – | – | – | -$2.97M | -$2.97M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$101.70M | -$120.12M | $15.23M | -$222.20M | -$64.42M |
| Net cash flow from continuing operations | -$101.70M | -$120.12M | $15.23M | -$222.20M | -$64.42M |
| Net Income from Continuing Operations | -$144.76M | -$106.16M | -$75.97M | -$141.20M | $33.00M |
| Depreciation & Depletion & Amortization | $61,000.00 | $551,000.00 | $576,000.00 | $1.33M | $412,000.00 |
| Other Non-Cash Items | $738,000.00 | $764,000.00 | $649,000.00 | $2.56M | $940,000.00 |
| Change in Working Capital | $32.70M | -$24.51M | $81.58M | -$88.04M | -$93.83M |
| -Change in Receivables | $0.00 | $0.00 | $100.00M | -$100.00M | -$100.00M |
| -Change in Prepaid Assets | -$5.78M | $2.72M | -$7.99M | -$16.41M | -$9.13M |
| -Change in Payables and Accrued Expense | $40.48M | $8.82M | -$5.10M | $26.28M | $10.02M |
| -Change in Other Current Assets | -$1.46M | -$35.44M | -$4.84M | $4.39M | $5.88M |
| -Change in Other Current Liabilities | -$539,000.00 | -$619,000.00 | -$489,000.00 | -$2.30M | -$603,000.00 |
| Net cash flow from investing | $50.36M | $74.50M | -$496.95M | $89.80M | $56.14M |
| Net Cash Flow from Continuing Investing Activities | $50.36M | $74.50M | -$496.95M | $89.80M | $56.14M |
| Net PPE Purchase and Sale | -$3.65M | $42,000.00 | -$1.18M | -$3.61M | -$1.50M |
| Net Investment Purchase and Sale | $54.01M | $74.46M | -$495.77M | $93.41M | $62.79M |
| Financing Cash Flow | $734,000.00 | $2.09M | -$1.74M | $762.52M | $704.99M |
| Net Cash Flow from Continuing Financing Activities | $734,000.00 | $2.09M | -$1.74M | $762.52M | $704.99M |
| Proceeds from Stock Option Exercised | $1.23M | $2.09M | $869,000.00 | $99.45M | $97.59M |
| Net Other Financing Charges | -$500,000.00 | $0.00 | -$2.61M | -$2.64M | -$1.25M |
| Ending Cash Balance | $222.03M | $272.64M | $316.17M | $799.62M | $799.62M |
| Net Change in Cash | -$50.61M | -$43.53M | -$483.46M | $630.11M | $696.71M |
| Beginning Cash Balance | $272.64M | $316.17M | $799.62M | $169.51M | $102.91M |
| Free Cash Flow | -$105.35M | -$120.07M | $14.05M | -$225.81M | -$65.91M |
| Gain/Loss from Continuing Operations | – | – | – | -$10.25M | – |
| Net Common Stock Issuance | – | – | – | $665.71M | $608.65M |
No comments yet — be the first to weigh in on GPCR.
Sign in to join the discussion.